APA (7th ed.) Citation

Li, B., Cheng, S., Xiao, J., Liu, S., & Tang, L. Tremelimumab plus durvalumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: A cost-effectiveness analysis from the US payer perspective. BMJ Publishing Group.

Chicago Style (17th ed.) Citation

Li, Bin, Shuqiao Cheng, Jian Xiao, Shao Liu, and Lanhua Tang. Tremelimumab Plus Durvalumab Versus Sorafenib in First-line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-effectiveness Analysis from the US Payer Perspective. BMJ Publishing Group.

MLA (9th ed.) Citation

Li, Bin, et al. Tremelimumab Plus Durvalumab Versus Sorafenib in First-line Treatment of Unresectable Hepatocellular Carcinoma: A Cost-effectiveness Analysis from the US Payer Perspective. BMJ Publishing Group.